What defines the category
503A compounding is patient specific. A prescription for an identified patient exists first, and the preparation is made against it. These pharmacies are regulated primarily at state board level, with federal conditions attached to the exemption.
Why an operator encounters the term
Anyone evaluating a prescribed telehealth model will meet 503A and 503B pharmacies as the fulfillment layer. That model is a genuinely different regulatory lane from research supply: it involves prescribers, patient relationships, and a prescription as the trigger for every unit dispensed.
Choosing between the lanes
Research supply and prescribed telehealth are not competing versions of the same business. They have
different buyers, different claim vocabulary, and different regulators. Operators should choose
deliberately rather than drift between them.